GLP-1 Drugs Like Ozempic May Cut Asthma Attacks by 40 Percent, New Research Shows

New research suggests that GLP-1 receptor agonist drugs, including semaglutide sold under the brand names Ozempic and Wegovy, may reduce asthma attacks by up to 40 percent.

The findings add to a growing list of potential benefits from this class of medications, which were originally developed for type 2 diabetes and later approved for weight loss.

Researchers believe the anti-inflammatory properties of GLP-1 drugs may play a role in reducing airway inflammation, which is a key driver of asthma attacks. The drugs may also help by reducing obesity, which is a known risk factor for severe asthma.

A separate review published in September found that GLP-1 medications, specifically tirzepatide sold as Zepbound, are effective in treating obstructive sleep apnea associated with obesity, particularly when used alongside CPAP therapy.

Scientists have also found that administering semaglutide to elderly mice extended their lifespan by an average of 12 percent, according to a study highlighted by the Global Wellness Institute.

The expanding evidence base for GLP-1 drugs has prompted researchers to investigate their potential in treating a wide range of conditions, including bipolar disorder, Alzheimer's disease, and addiction.

However, AI analysis of user-reported data has also identified unexpected side effects from GLP-1 drugs, including fatigue and menstrual changes. Researchers say more long-term studies are needed to fully understand the risks and benefits.

The drugs remain expensive and are not covered by all insurance plans, limiting access for many patients who might benefit from them.